New York, NY, and Columbus, OH, March 2, 2022 – SpringCreek Fertility, an Ohio-based, regional leader in reproductive endocrinology, and Albaron Partners, LP (“Albaron”), a U.S. private equity firm focused on acquiring majority stakes of companies in the specialty healthcare services sector, today announced that SpringCreek Fertility has been acquired by affiliates of Albaron. SpringCreek Fertility will become part of Innovation Fertility, Albaron’s reproductive endocrinology platform. The financial terms of the transaction were not disclosed. Company Founder and Chief Medical Officer, Dr. Jeremy Groll, has retained a minority ownership stake in SpringCreek Fertility.


Based in Columbus, OH, SpringCreek Fertility is a state-of-the-art fertility center offering comprehensive reproductive health care treatment options, including in vitro fertilization, egg donation, genetic testing, intrauterine insemination, egg freezing and gestational carrying. Founded in 2014 by Dr. Jeremy Groll, the award-winning term of fertility specialists at SpringCreek Fertility complete around 600 IVF cycles each year. For more information, visit:


Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine some of the premier reproductive endocrinologists of the world with the most experienced laboratory managers and operators in the space, resulting in exceptional medical care and an unparalleled patient experience. For more information, visit:


Albaron is a U.S. private equity firm that invests in and helps accelerate the growth of physician practice groups and microcap healthcare companies. The firm’s goal is to build best-in-class healthcare services platforms that maximize outcomes for all constituents – patients, providers, payors and investors. Albaron’s team is comprised of a seasoned cohort of operating experts and investment professionals who are uniquely qualified to realize significant value through strategic insights, operating support and accretive acquisitions. The team works collaboratively with partnering management teams and leverages its network of industry experts to augment its capabilities. For more information, visit:


This communication expressly or implicitly contains certain forward-looking statements that involve risks and uncertainties, including statements regarding expectations for SpringCreek Fertility following its acquisition by Albaron. If any of these risks or uncertainties materialize, or if any of SpringCreek Fertility’s or Albaron’s assumptions prove incorrect, SpringCreek Fertility’s results could differ materially from the results expressed or implied by these forward-looking statements. All forward-looking statements in this communication are based on information available to SpringCreek Fertility and Albaron as of the date of this communication, and SpringCreek Fertility and Albaron do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.